Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases.

M, Silacci; W, Lembke; R, Woods; I, Attinger-Toller; N, Baenziger-Tobler; S, Batey; R, Santimaria; der Bey U, von; S, Koenig-Friedrich; W, Zha; B, Schlereth; M, Locher; J, Bertschinger; D, Grabulovski

doi:10.1080/19420862.2015.1093266

Public

Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases.

Shared by NobleBlocks on Sep 22, 2015 • 12:00 AM UTC

Authors:

Silacci M

Lembke W

Woods R

Abstract

Biologic treatment options such as tumor necrosis factor (TNF) inhibitors have revolutionized the treatment of inflammatory diseases, including rheumatoid arthritis. Recent data suggest, however, that full and long-lasting responses to TNF inhibitors are limited because of the activation of the pro-...

Subject

Bispecific antibody

TNF

Il-17

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!